SCHEDULE: JPMorgan Chase Amends Bristol-Myers Squibb Stake
Beneficial Ownership Disclosure (Schedule 13G Amendment)
JPMorgan Chase & Co. has filed an amendment to its Schedule 13G, disclosing a 4.0% beneficial ownership stake in Bristol-Myers Squibb Company as of September 30, 2025.
Summary
- JPMorgan Chase & Co. reported beneficial ownership of 81,890,781 shares of Bristol-Myers Squibb Company common stock.
- This represents 4.0% of the class of securities.
- The filing is an Amendment No. 1 to a Schedule 13G.
- The event date requiring this filing was September 30, 2025.
- JPMorgan Chase & Co. holds these securities in the ordinary course of business and not for the purpose of changing or influencing control of Bristol-Myers Squibb.
Sentiment
Score: 5
Explanation: The filing is a neutral, factual disclosure of beneficial ownership, indicating a passive investment by a major financial institution without expressing positive or negative sentiment about the issuer's performance.
Positives
- JPMorgan Chase & Co. maintains a significant, albeit passive, investment in Bristol-Myers Squibb, indicating continued confidence in the company's long-term prospects from a major financial institution.
Negatives
- The filing itself does not present any negative information regarding Bristol-Myers Squibb's operations or financial health. It is a disclosure of ownership.
Risks
- The filing does not explicitly mention risks related to Bristol-Myers Squibb's business. It certifies that the investment is not for control purposes, mitigating a potential risk of activist investor intervention from JPMorgan.
Future Outlook
NA
Industry Context
Bristol-Myers Squibb operates in the global pharmaceutical industry, focusing on discovering, developing, manufacturing, and marketing innovative medicines. JPMorgan Chase & Co.'s passive stake reflects a financial institution's investment in a major player within this sector, which is characterized by significant R&D investments, patent protection, and regulatory oversight.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Ownership Certification | JPMorgan Chase & Co. certified that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Bristol-Myers Squibb Company. | 09/30/2025 | This certification indicates a passive investment strategy, reassuring other investors that JPMorgan Chase is not pursuing an activist role or seeking to alter the company's governance structure. |
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's stake, potentially offering a degree of confidence in the company's long-term value proposition.
- Management: Reassures management that this large stake is passive and not intended to influence control.
Key Dates
| Date | Description |
|---|---|
| 09/30/2025 | Date of event requiring the filing of this statement |
| 10/31/2025 | Signature date of the filing |
Keywords
JPMorgan Chase, Bristol-Myers Squibb, Beneficial Ownership, Schedule 13G, Common Stock, Pharmaceuticals, Institutional Investment, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.